Articles tagged with Drug Resistance
Researchers found that immune cells were six times more active in tumours resistant to cetuximab. Immunotherapies designed to boost the immune system could be effective against these cancers. A phase II clinical trial has begun to test this approach.
A team of researchers has discovered a new way to target the unique metabolism of drug-resistant parasites, using a molecule called rhodoquinone. This approach could lead to the development of new drugs that selectively kill parasites without harming humans.
A Duke University study identifies over 100 human genes co-opted by malaria parasites during the silent earlier stages of infection. This finding could lead to new treatments and prevent the disease from spreading.
The University of Illinois Chicago is collaborating with TB Alliance to develop new clinical-stage drug candidates for treating tuberculosis, a bacterial infection resistant to available antibiotics. The five-year research project aims to produce two new treatments, with UIC receiving up to $9 million in funding.
IDIBELL researchers have discovered a biomarker that predicts resistance to the chemotherapy drug docetaxel in triple-negative breast cancer. The study found that tumors with an amplified chromosome 12 region are more likely to develop resistance to docetaxel, but may be vulnerable to alternative treatment with carboplatin.
Researchers at Oregon State University have discovered two compounds, deguelin and rotenone, that can inhibit the metabolism of melanoma cancer cells, effectively starving them of energy. This breakthrough offers a new potential treatment option for drug-resistant metastatic melanoma.
A new assay has been developed to detect patients' resistance to antimalarial drugs using whole blood, providing critical information quickly and efficiently in resource-limited settings. The technique eliminates DNA extraction steps, allowing for faster and more accurate assessment of genetic data associated with drug resistance.
Researchers identified a previously unknown pocket on the surface of picornaviruses, which can be stabilized by a newly-discovered compound. This stabilization prevents shape change and interaction with host cells, making it a promising strategy for developing antiviral medications.
Scientists have discovered a small molecule drug that can stop cancer cells from becoming resistant to chemotherapy. The compound, JH-RE-06, works by thwarting cancer's ability to survive and adapt to DNA damage caused by traditional chemotherapy drugs like cisplatin.
Susan Band Horwitz, an NFCR fellow, has been named a Giant of Cancer Care for her pioneering work on Taxol and its role in stabilizing microtubules to prevent cancer cell growth. Her research enabled the development of life-saving medications for ovarian, breast, and lung cancers.
Researchers at University of Malaga identify a fragment of the brain molecule Galanin as involved in anhedonia, a key symptom of depression. The study suggests potential new therapeutic strategies for treating depression and related addictions.
BCL-2 protein deregulation and transcriptional reprogramming contribute to Venetoclax resistance; researchers suggest targeting CDK7 as effective strategy to prevent resistance. Studies provide insights into drug resistance mechanism in B-cell lymphomas, paving way for potential co-treatment strategies.
Scientists at the Francis Crick Institute and Imperial College London have identified novel compounds that target a different part of the malaria parasite's enzyme, evading the same resistance mechanism. This study aimed to prevent malaria treatment resistance by studying how it evolves during drug development.
Researchers at MD Anderson Cancer Center discovered a small molecule drug, IACS-10759, that targets metabolic reprogramming and inhibits OXPHOS, leading to marked growth inhibition in ibrutinib-resistant mantle cell lymphoma cells. The study provides hope for patients with this incurable B-cell lymphoma.
Cancer cells' acquired resistance to anti-cancer drugs can be exploited as an Achilles heel, according to research that shows removing a MEK1/2 inhibitor drug causes reversal of drug resistance in colon cancer cell populations. This finding may inform decisions about intermittent use rather than continuous exposure.
Researchers at the University of Lincoln have successfully reproduced the complex 'anti-tumour antibiotic' kedarcidin, which shows promise in treating cancer and combating drug-resistant bacteria. The breakthrough could lead to new antibiotics and anticancer agents, offering hope for millions facing life-threatening infections.
A new study by researchers at the University of Illinois found that combining two cancer drugs, selinexor and 4-OHT, may prevent endocrine resistance in breast tumors. The treatment protocol was more effective than either drug alone in reducing tumor cells' viability.
A DNA rearrangement in immunoglobulin lambda (IgL) translocations is associated with poorer outcomes and reduced survival benefit from immunomodulatory drugs like lenalidomide. Patients with this genetic marker are more likely to relapse and die within the first three years after diagnosis.
Researchers have shed light on how leukemia cells become resistant to drugs and describe a potential solution using two drugs in combination. The study identifies the genes responsible for resistance, revealing that cancer cells overcome the lack of asparagine by breaking down proteins.
Moffitt researchers discovered that melanoma cells become resistant to BRAF inhibitors through a conserved stress response mechanism involving AP-1 activation and histone deacetylase 8. This finding suggests that HDAC inhibitors may be able to overcome resistance mechanisms, leading to potential new treatments.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
A collaborative research project has identified a previously uncharacterised genetic mutation in clinical isolates leading to resistance. The finding challenges current paradigms and paves the way for designing changes in therapy to overcome antifungal-resistant diseases.
Researchers develop drugs targeting specific component of folate pathway, potentially addressing drug resistance and treatment time. The compounds are more effective than existing antifolate medication PAS, offering hope for new treatment options.
A research collaboration between Columbia University and a genomicist has identified specific genetic pathways associated with antidepressant resistance. The team hopes to develop new treatments that can circumvent resistance in millions of people who do not respond to current medications.
Researchers at ISGlobal and ITM discovered that P. falciparum populations can develop resistance to certain antimalarial compounds by epigenetic changes in the expression of clag3 genes. This finding is significant because resistance acquired through epigenetic mechanisms can arise quickly, even during a single infection.
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
Scientists at Kanazawa University found that AXL protein is responsible for resistance to osimertinib, a tyrosine kinase inhibitor used to treat EGFR-mutated lung cancer. Inhibiting AXL expression can prevent tumor regrowth and improve treatment outcomes.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers develop a new assay to measure the eco-evolutionary interactions between sensitive and resistant tumor cells in non-small cell lung cancer. The study finds that by applying drug or eliminating fibroblasts, it is possible to 'treat the game', allowing for coopting of evolution to help patients
Researchers discovered that fluconazole treatment makes fungi sexually active, combining different resistance mechanisms and producing highly resistant offspring. This finding can help develop better drugs and overcome resistance.
A recent study found that many cases of drug-resistant tuberculosis remain undetected due to inaccurate tests, leading to incorrect treatment and higher mortality rates. The researchers recommend developing new, comprehensive point-of-care molecular tests that can deliver results within hours or days.
A class of breast cancer drugs could potentially benefit patients with EGFR-mutant lung cancers that have become resistant to treatment. Lung tumours in mice caused by mutations in a gene called EGFR shrunk significantly when a protein called p110α was blocked.
Case Western Reserve University researcher Sanjay Gupta has been awarded nearly $1 million to investigate drug resistance mechanisms in prostate cancer. He will test two promising medications, simvastatin and metformin, to overcome drug resistance and halt metastasis.
Researchers at SUTD and NTU developed ferrocene-based molecules that impair malaria parasite's metabolic function, leading to parasite death. G3, a gold complexed ferrocinyl phosphine derivative, demonstrated potent antimalarial activity against standard and drug-resistant strains.
Research identifies chain reaction in cells that helps cancer survive BRAF and MEK treatment. A new process called ER translocation connects two common resistance mechanisms, increasing autophagy and drug resistance.
The study suggests using CCBs and RAAS blockades in combination to reduce albuminuria, while also advising low-salt intake and different antihypertensive drugs for resistant hypertension. Multifactorial and early treatment is recommended for patients with albuminuria values below the cut-off value.
David Cheresh, a renowned cancer researcher, has received a $4.2 million NCI award to investigate how tumors adapt to stress and develop drug resistance. His research aims to find ways to perturb the malignant cell version of wound repair, potentially eliminating highly drug-resistant cancers.
Researchers have identified NSD2 as a new vulnerability in aggressive, metastatic prostate cancers that have become resistant to hormonal therapies. The study suggests a combined therapeutic approach using an NSD2 inhibitor drug with conventional antiandrogenic drugs to re-sensitize resistant tumors.
A new study suggests combining kinase inhibitors with ribonucleases could lead to better results against melanoma. The combination kills cells more effectively than either drug alone, potentially preventing tumor resistance. Researchers hope to test the combination in clinical trials.
Researchers have discovered a new way to target drug-resistant tumors by combining EGFR and Aurora Kinase A inhibitors. Elevated levels of TPX2 protein in biopsies can predict tumor susceptibility to combined therapies.
Researchers have generated a novel mouse model with a humanized cereblon receptor to study the effects of immunomodulatory drugs. The new mice respond to treatment with these drugs, revealing distinct therapeutic pathways for immunomodulation.
Researchers developed a new oral immunotherapy drug, AR101, derived from peanut protein, to build tolerance in peanut allergy sufferers. The study found that more than two-thirds of participants taking the active drug could tolerate a dose of peanut protein equivalent to about two peanut kernels.
Researchers have discovered previously unidentified mutations in the PfCoronin and PfKelch13 genes that confer artemisinin resistance in West African malaria strains. These findings provide potential insights into the molecular mechanisms of artemisinin resistance.
Researchers have developed a new technique that accelerates and simplifies the directed evolution bioengineering method, allowing for rapid mutation and evolution of genes in yeast cells. This breakthrough enables scientists to perform multiple evolutionary cycles continuously, leading to faster discovery of new proteins and enzymes.
Researchers discovered that melanomas produce BRAF proteins that become active complexes with MEK, making them resistant to RAF-inhibiting drugs. Blocking this complex can restore the potency of the therapy.
Researchers found that targeted therapies could be more effective in treating TB, which killed an estimated 1.3 million people worldwide last year. Patients with minimal disease showed high efficacy with four-month treatments, while those with moderate or severe disease required longer treatment durations.
A NUS study found that overexpression of ADAR1 and irregular RNA editing of NEIL1 are key factors in MM progression and drug resistance. The study offers novel insights for new therapeutic strategies.
Biologists at UC San Diego have discovered a human gene that inhibits HIV and makes tumor cells sensitive to DNA-damaging agents. The researchers found that the Schlafen 11 protein blocks the synthesis of viral proteins, allowing tumor cells to survive.
Biophysicists at Ruhr-University Bochum developed a Raman microscopy method to detect cancer drug resistance in tumour cells. The new approach shows effectiveness in non-mutated cells but remains ineffective in mutated cells, similar to clinical observations.
A recent study by Imperial College London suggests that the flu virus can develop resistance to favipiravir, a potential pandemic drug, if it undergoes two specific genetic mutations. This finding highlights the need for close monitoring and surveillance to prevent the emergence of resistant strains.
Researchers found an association between lead levels in the shin bone and treatment-resistant high blood pressure in men. The study suggests that cumulative lead burden may be an overlooked risk factor for drug-resistant hypertension.
A new study suggests that a monthly vaginal ring releasing dapivirine, an antiretroviral drug, poses minimal risk of developing drug-resistant HIV. The research analyzed plasma samples from women who acquired HIV during the ASPIRE Phase III trial and found no cases of dapivirine-associated resistance.
Researchers have identified two compounds with better antiviral properties than oseltamivir, effective against both drug-resistant and sensitive strains of influenza A. These compounds target the AM2 protein with the S31N mutation, a key site of resistance in most influenza A viruses.
The study identifies 14 common chemicals that can impact assay conclusions without compromising plasmodium growth and proliferation. The team estimates maximum allowable concentrations compatible with the assay, ensuring normal parasite survival and proliferation.
Sanjay Awasthi's research blocks stress-responsive protein Rlip to defeat deleterious effects of p53 loss, a common genetic defect in breast cancers. This discovery could lead to effective new medications for cancer, diabetes, and other health issues.
Dr Alison Feder's innovative work on HIV's high mutation rates and large population sizes has been recognized with the inaugural Milner Prize. Her research explores how drug resistance evolution affects patient dynamics, shedding light on the complex interactions between viruses and their hosts.
Researchers at Wayne State University have developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs to reverse drug-resistance in renal cell carcinoma. The technology uses tumor hypoxia-directed nanoparticles to target the root cause of the problem and has shown promising results in animal trials.
Resistant hypertension affects 12-15% of patients with high blood pressure, who require three or more medications to control it. Improving lifestyle factors such as diet, physical activity, and weight can lower blood pressure.